Hepatic steatosis, GH deficiency and the effects of GH replacement: a Liverpool magnetic resonance spectroscopy study

Eur J Endocrinol. 2012 Jun;166(6):993-1002. doi: 10.1530/EJE-12-0002. Epub 2012 Mar 20.

Abstract

Objective: Non-alcoholic fatty liver disease (NAFLD) is reported to be more common in patients with GH deficiency (GHD) than in the general population. we aimed to determine: i) liver fat in patients with GHD compared with age and body mass index (BMI)-matched controls; and ii) effect of 6 months of GH replacement (GHR) on liver fat.

Participants and methods: The study included 28 GHD patients and 24 controls. 12 patients were studied before and after 6 months of GHR. Anthropometry, liver enzymes and lipid profiles were measured, and body composition and intrahepatocellular lipid (IHCL) were determined by magnetic resonance imaging and spectroscopy.

Results: Age and BMI (median (inter-quartile range)) of patients and controls were 52.6 (14) vs 52.6 (12) years (P=0.9) and 27.8 (24.7, 34.7) vs 27.9 (25.1, 32.1) kg/m(2) (P=0.9). IGF1 was lower in the patients (11.5 vs 16.0 nmol/l, P=0.002). There was no difference in liver transaminases, lipids or IHCL between patients and controls (2.8 (1.3, 8.6) vs 5.0 (1.5, 12.7), P=0.72), despite significantly higher visceral fat in GHD patients. Thirty-two percent of patients and 50% of controls had NAFLD (defined as IHCL >5.6%), and the relationship between IHCL and BMI was the same in each group. GHR significantly reduced abdominal subcutaneous and visceral fat in all patients; however, GHR did not reduce liver fat.

Conclusions: NAFLD is equally common in patients with GHD and matched controls. GHR is associated with a hierarchical reduction in fat deposition (fat loss: visceral > subcutaneous > liver). Further studies involving GHD patients with NAFLD are required to conclude the role of GHR in treating NAFLD.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Age Factors
  • Aged
  • Body Composition
  • Body Mass Index
  • Case-Control Studies
  • Cross-Sectional Studies
  • England / epidemiology
  • Fatty Liver / epidemiology
  • Fatty Liver / metabolism*
  • Fatty Liver / pathology*
  • Female
  • Hepatocytes / metabolism
  • Hormone Replacement Therapy* / methods
  • Human Growth Hormone / administration & dosage*
  • Human Growth Hormone / deficiency*
  • Humans
  • Intra-Abdominal Fat* / metabolism
  • Intra-Abdominal Fat* / pathology
  • Lipid Metabolism*
  • Magnetic Resonance Imaging
  • Magnetic Resonance Spectroscopy*
  • Male
  • Middle Aged
  • Non-alcoholic Fatty Liver Disease
  • Protons
  • Subcutaneous Fat / metabolism
  • Subcutaneous Fat / pathology
  • Time Factors

Substances

  • Protons
  • Human Growth Hormone